Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes
Completed · Phase 1/Phase 2
Conditions studied: Leukemia, Myelodysplastic Syndromes
In brief
RATIONALE: Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Lenalidomide may also stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Azacitidine may also cause cancer cells to look more like normal cells, and to grow and spread more slowly. Giving lenalidomide together with azacitidine may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of lenalidomide and azacitidine in treating patients with advanced myelodysplastic syndromes.
Key facts
- Study ID
- NCT00352001
- Run by
- Mikkael Sekeres MD
- People needed
- 37
- Starts
- 2006-05-01
- Expected to finish
- 2011-09-01
- Last updated by the study team
- 2018-09-19
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California at Los Angeles — Los Angeles, California, United States
- H. Lee Moffitt Cancer Center and Research Institute at University of South Florida — Tampa, Florida, United States
- Cleveland Clinic Taussig Cancer Instititute, Case Comprehensive Cancer Center — Cleveland, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.